Geneva — Drug maker Eli Lilly will offer a half-priced version of its blockbuster insulin, becoming one of the first companies to effectively cut the price of a top-selling drug amid the ongoing US debate over pharmaceutical costs. While it will continue selling its brand-name version at the existing price, Lilly will also sell a half-cost “authorised generic” for $137.35 a vial, or $265.20 for a five-pack of injectable pens. That will give a better deal to customers who pay cash, or who are in insurance plans that make them pay a percentage of a drug’s list price. Insurers and pharmacy benefit managers (PBMs) do not typically pay the listed prices for drugs, and instead negotiate discounts and rebates that can help lower premiums as a whole, but that can result in large out-of-pocket costs for some patients on costly medicine or who have chronic conditions that force them to take treatments year-round. “The significant rebates we pay on insulins do not directly benefit all patients...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.